BioCentury and Nature Publishing Group Release a Roadmap to

BioCentury and Nature Publishing Group Release a Roadmap to
Innovation for an Emerging Class of Therapies 
Groundbreaking Report Identifies Translational Hurdles and Suggests
Action Plans for Progress in the Field of Macrocycles & Constrained
Peptides 
REDWOOD CITY, CA and NEW YORK, NY -- (Marketwire) -- 11/15/12 -- 
SciBX: Science-Business eXchange today announced the publication of
"Bringing Macrocycles Full Circle," a Roadmap to Innovation in the
field of macrocycles and constrained peptides. This first-of-its-kind
SciBX Roadmap to Innovation is being published in the November 15
edition of SciBX, a joint venture between BioCentury Publications,
Inc., the internationally respected source of biopharma business
intelligence, and Nature Publishing Group (NPG), a leading publisher
of high impact scientific and medical information. SciBX identifies
commercially promising translational science and assesses the next
steps required to develop it. 
The Roadmap identifies four critical areas in the macrocycle space
where more research is needed to advance a field that promises to
reach therapeutic targets that have been inaccessible to existing
small molecule drugs and biologics. More effort in three of these
areas -- pharmacokinetics, cell permeability and oral bioavailability
-- would create an understanding of the rules that govern the
behavior of macrocycles and thus enable developers to better identify
drug-like compounds. The fourth critical area is the issue of how
macrocycles engage their targets.  
The Roadmap is available for download at
http://www.nature.com/scibx/journal/v5/n45/full/scibx.2012.1176.html. 
"Bringing Macrocycles Full Circle" is the result of the inaugural
SciBX Summit on Innovation in Drug Discovery & Development. The
Summit was organized by BioCentury and Nature Publishing Group and
sponsored by Aileron Therapeutics Inc.; Amgen Inc. (AMGN);
BioDuro/PPD Inc. (PPDI); Ipsen (IPN; IPSEY); MedImmune LLC;
PeptiDream Inc.; Sanofi (SAN; SNY); Sofinnova Ventures; Takeda
Pharmaceutical Co. Ltd. (4502); and Third Rock Ventures. 
The Summit culminated the work of a "think tank" of key opinion
leaders from academia, biotech, pharma and the investment community,
organized and moderated by the SciBX editorial team over the summer.
The think tank consis
ted of Bruce Booth, Partner at Atlas Venture;
Spiros Liras, Vice President of Cardiovascular, Metabolic and
Endocrine Medicinal Chemistry at Pfizer Inc. (PFE); Barry Morgan,
Vice President of Molecular Discovery Research at GlaxoSmithKline plc
(GSK); Patrick Reid, Co-Founder & Chief Scientific Officer at
PeptiDream; Tomi Sawyer, Chief Scientific Officer and Senior Vice
President of Drug Discovery & Innovative Technologies at Aileron; and
Gregory Verdine, Professor at Harvard University and Venture Partner
at Third Rock Ventures.  
The think tank convened with other key opinion leaders, including
CEOs and CSOs of macrocycle companies and top academics in the field,
at the recent SciBX Summit in Boston to discuss the challenges and
opportunities afforded by the field and how to best direct efforts
towards realizing its innovation potential. 
The Roadmap includes calls by the Summit participants for the
establishment of precompetitive collaborations to tackle challenges
such as the systematic study of which macrocycles pass into cells,
and for the prioritization by the National Institutes of Health (NIH)
and other funding agencies of initiatives to improve our
understanding of key underlying biological mechanisms.  
"The unique approach to these Summits, consisting of in depth
discussions with the members of the think tank and culminating with
an open forum with additional key stake holders, allowed the SciBX
editorial team to generate an independent and detailed Roadmap to
Innovation in the macrocycle space that presents a one-of-a-kind
perspective of what will be needed to make innovation happen," said
Gaspar Taroncher-Oldenburg, Managing Editor and Associate Publisher
of SciBX. 
"The goal of the SciBX Summit initiative was to address an unmet need
for key opinion leaders to reach consensus on how to overcome
roadblocks to drug innovation," said Karen Bernstein, Chairman and
Editor-in-Chief of BioCentury. "The resulting SciBX Roadmap to
Innovation provides a template for our future efforts with Nature
Publishing Group as we address other translational challenges that
must be solved to bring healthcare innovation to patients." 
The SciBX editorial team is already preparing for the next SciBX
Summit in 2013. The editors are considering new targets, pathways and
therapeutic approaches that will become the subject of the next SciBX
Roadmap for Innovation.  
For information about sponsoring the next SciBX Summit, contact
Thomas Carey at BioCentury, or Claire Thompson at Nature Publishing
Group. 
About Macrocycles & Constrained Peptides 
Molecules in the 500-5,000 Da size range have burst onto the drug
discovery stage as a way to bridge the gap between small molecules
and biologics. The hope is that these molecular entities will combine
the pharmacological properties of small molecules with the
specificity of biologics to address intracellular protein-protein
interactions that have been considered undruggable. 
About BioCentury 
Now in its 20th year, BioCentury Publications, Inc. provides
essential biopharma industry intelligence to a global audience of
biotech and pharmaceutical executives, investors, regulators and
public policy makers, and the scientific community. This audience has
benefited from BioCentury's deep knowledge, data-driven analysis,
independent perspective and trustworthy content available through the
company's publications, data products and collaborative industry
conferences in the U.S., Europe and Asia. 
BioCentury's titles include the flagship BioCentury(R), the Bernstein
Report on BioBusiness; its SciBX: Science-Business eXchange(TM)
translational science partnership with Nature Publishing Group; and
its BioCentury Extra(TM) online daily newspaper. These timely
journals are backed by BCIQ: BioCentury Online Intelligence(TM), an
online business intelligence resource. BioCentury also produces its
BioCentury This Week biotech public affairs television program in
partnership with the Gannett-owned WUSA9 CBS affiliate in Washington,
D.C. The program is aired in Washington each Sunday as part of the
WUSA9 "Sunday Morning Power Block," and distributed globally online
at www.biocenturytv.com. 
For more information, visit www.biocentury.com and
www.biocenturytv.com. 
About Nature Publishing Group (NPG) 
Nature Publishing Group (NPG) is a publisher of high impact
scientific and medical information in print and online. NPG publishes
journals, online databases and services across the life, physical,
chemical and applied sciences and clinical medicine.  
Focusing on the needs of scientists, Nature (founded in 1869) is the
leading weekly, international scientific journal. In addition, for
this audience, NPG publishes a range of Nature research journals and
Nature Reviews journals, plus a range of prestigious academic
journals including society-owned publications. Online, nature.com
provides over 6 million visitors per month with access to NPG
publications and online databases and services, including news and
comment from Nature, NatureJobs plus access to Nature Network and
Nature Education's Scitable.com. 
Scientific American is at the heart of NPG's consumer media division,
meeting the needs of the general public. Founded in 1845, Scientific
American is the oldest
 continuously published magazine in the US and
the leading authoritative publication for science in the general
media. Together with scientificamerican.com and 14 local language
editions around the world it reaches over 5 million consumers and
scientists. Other titles include Scientific American Mind and
Spektrum der Wissenschaft in Germany. 
Throughout all its businesses NPG is dedicated to serving the
scientific and medical communities and the wider scientifically
interested general public. Part of Macmillan Publishers Limited, NPG
is a global company with principal offices in London, New York and
Tokyo, and offices in cities worldwide including Boston, Buenos
Aires, Cairo, Delhi, Mumbai, Hong Kong, Madrid, Barcelona, Munich,
Heidelberg, Basingstoke, Melbourne, Paris, San Francisco, Seoul and
Washington DC. For more information, please go to www.nature.com. 
Contact Information:
Thomas Carey
BioCentury Publications, Inc.
+1-650-595-5333
tcarey@biocentury.com  
Rachel Scheer
Nature Publishing Group
+1-212-451-8569
r.scheer@us.nature.com 
 
 
Press spacebar to pause and continue. Press esc to stop.